查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1435471

2024 年寡核苷酸治療全球市場報告

Oligonucleotide Therapy Global Market Report 2024
出版日期: 按訂單生產 | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

寡核苷酸治療市場規模預計在未來幾年將快速成長。預計到 2028 年將以 11.8% 的複合年成長率 (CAGR) 成長至 87.5 億美元。預測期的延長可歸因於研發投資的增加、全球市場滲透、治療領域的擴大、疾病改善策略和監管適應。預測期內的主要趨勢包括個人化治療、遞送系統的進步、 RNA干擾（RNAi）的創新、反義寡核苷酸的進步以及基因編輯技術的整合。

預計全球癌症病例的增加將有助於預測期內寡核苷酸治療市場的成長。例如，截至 2022 年 1 月，美國癌症協會報告稱，美國約有 190 萬例新診斷癌症和 609,360 例癌症相關死亡，平均每天約有 1,670 例死亡。肺癌、攝護腺癌和腸癌是全球最常見的癌症類型，而女性乳癌佔所有新癌症病例的 43%。因此，全球癌症發生率的快速增加預計將增加未來幾年對寡核苷酸治療市場的需求。

旨在醫學研究和開發的政府措施預計將推動寡核苷酸治療市場的成長。這些措施涉及各級政府（地方、區域、國家或國際）解決具體問題、實現既定目標或促進社會積極變革。它包括當局採取的具體行動、計劃、政策或計劃。各政府機構已經推出了支持寡核苷酸治療等各方面的醫療舉措。據英國衛生和社會保障部稱，英國政府已承諾在 2022 年提供 2.6 億英鎊（2.7065 億美元）資金用於加強醫學研究和製造。該資金由 BEIS 和 DHSC 提供，旨在透過新的隱私保護平台和臨床研究服務來支持 NHS主導的診斷​​和治療健康研究。也撥款 6,000 萬英鎊（6,360 萬美元）用於支持英國生命科學製造業的擴張。

目錄

第1章執行摘要

第2章 市場特點

第3章 市場趨勢與策略

第4章宏觀經濟情景

  • 高通膨對市場的影響
  • 烏克蘭與俄羅斯戰爭對市場的影響
  • COVID-19 對市場的影響

第5章世界市場規模與成長

  • 全球寡核苷酸治療市場的驅動與限制因素
    • 市場促進因素
    • 市場限制因素
  • 2018-2023年全球寡核苷酸治療市場規模表現與成長
  • 2023-2028、2033年全球寡核苷酸治療市場規模及成長預測

第6章市場區隔

  • 全球寡核苷酸治療市場，按類型、實際和預測細分，2018-2023、2023-2028、2033
  • 反義寡核苷酸
  • 適體
  • 其他
  • 全球寡核苷酸治療市場，按應用、效能和預測細分，2018-2023、2023-2028、2033
  • 感染疾病
  • 瘤
  • 神經退化性疾病
  • 心血管疾病
  • 腎臟疾病
  • 其他
  • 全球寡核苷酸治療市場，按最終用戶細分，實際和預測，2018-2023、2023-2028、2033
  • 醫院
  • 研究機構

第 7 章 區域與國家分析

  • 全球寡核苷酸治療市場，按地區、績效及預測，2018-2023、2023-2028、2033
  • 全球寡核苷酸治療市場，依國家、績效及預測，2018-2023、2023-2028、2033

第8章亞太市場

第9章 中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章 義大利市場

第20章 西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章加拿大市場

第26章 南美洲市場

第27章 巴西市場

第28章 中東市場

第29章 非洲市場

第30章 競爭形勢及公司概況

  • 寡核苷酸治療市場競爭形勢
  • 寡核苷酸治療市場公司概況
    • Pfizer Inc.
    • Merck &Co. Inc.
    • GlaxoSmithKline plc
    • Gelead Sciences Inc.
    • BioNTech SE

第31章 其他大型創新公司

  • Moderna Inc.
  • Biogen Inc.
  • Bausch+Lomb Company
  • Jazz Pharmaceuticals plc
  • QIAGEN Company
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Dynavax Technologies Corp.
  • Ionis Pharmaceuticals Inc.
  • Akcea Therapeutics Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Dicerna Pharmaceuticals lnc.
  • SomaGenics Inc.
  • Wave Life Sciences Ltd.
  • Exicure Inc.

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章 重大併購

第35章 未來前景與潛力分析

第36章附錄

簡介目錄
Product Code: r15191

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The expansion in the historical period can be attributed to increased investments in research and development, the introduction of early therapies to the market, advancements in gene editing techniques, initial therapeutic discoveries, and the introduction of RNAi and antisense oligonucleotides.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The expansion in the forecast period can be attributed to increased investments in research and development, global market penetration, the expansion of therapeutic areas, strategies for disease modification, and regulatory adaptations. Major trends in the forecast period include personalized therapies, advancements in delivery systems, innovations in RNA interference (RNAi), advancements in antisense oligonucleotides, and the integration of gene editing techniques.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

The oligonucleotide therapy market faced challenges during the forecast period due to the FDA's limited number of drug approvals. In 2022, the National Library of Medicine reported that only 37 new drug entities were approved, marking the lowest number since 2016. This can be attributed to stringent manufacturing standards and high efficacy criteria set by regulatory bodies for therapy approval, leading to prolonged approval timelines and restricting market growth.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals PLC, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Phrmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeuutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2023. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gelead Sciences Inc.; BioNTech SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Oligonucleotide Therapy Market Size and Growth

  • 5.1. Global Oligonucleotide Therapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Oligonucleotide Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oligonucleotide Therapy Market Segmentation

  • 6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antisense Oligonucleotide
  • Aptamer
  • Other Types
  • 6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other End-User
  • 6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Institutes

7. Oligonucleotide Therapy Market Regional And Country Analysis

  • 7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

  • 8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oligonucleotide Therapy Market

  • 9.1. China Oligonucleotide Therapy Market Overview
  • 9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oligonucleotide Therapy Market

  • 10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oligonucleotide Therapy Market

  • 11.1. Japan Oligonucleotide Therapy Market Overview
  • 11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oligonucleotide Therapy Market

  • 12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

  • 13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oligonucleotide Therapy Market

  • 14.1. South Korea Oligonucleotide Therapy Market Overview
  • 14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

  • 15.1. Western Europe Oligonucleotide Therapy Market Overview
  • 15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oligonucleotide Therapy Market

  • 16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oligonucleotide Therapy Market

  • 17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oligonucleotide Therapy Market

  • 18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oligonucleotide Therapy Market

  • 19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oligonucleotide Therapy Market

  • 20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

  • 21.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • 21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oligonucleotide Therapy Market

  • 22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oligonucleotide Therapy Market

  • 23.1. North America Oligonucleotide Therapy Market Overview
  • 23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oligonucleotide Therapy Market

  • 24.1. USA Oligonucleotide Therapy Market Overview
  • 24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oligonucleotide Therapy Market

  • 25.1. Canada Oligonucleotide Therapy Market Overview
  • 25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oligonucleotide Therapy Market

  • 26.1. South America Oligonucleotide Therapy Market Overview
  • 26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oligonucleotide Therapy Market

  • 27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oligonucleotide Therapy Market

  • 28.1. Middle East Oligonucleotide Therapy Market Overview
  • 28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oligonucleotide Therapy Market

  • 29.1. Africa Oligonucleotide Therapy Market Overview
  • 29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Oligonucleotide Therapy Market Competitive Landscape
  • 30.2. Oligonucleotide Therapy Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. GlaxoSmithKline plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Gelead Sciences Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. BioNTech SE
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • 31.1. Moderna Inc.
  • 31.2. Biogen Inc.
  • 31.3. Bausch + Lomb Company
  • 31.4. Jazz Pharmaceuticals plc
  • 31.5. QIAGEN Company
  • 31.6. Alnylam Pharmaceuticals Inc.
  • 31.7. Sarepta Therapeutics Inc.
  • 31.8. Dynavax Technologies Corp.
  • 31.9. Ionis Pharmaceuticals Inc.
  • 31.10. Akcea Therapeutics Inc.
  • 31.11. Arrowhead Pharmaceuticals Inc.
  • 31.12. Dicerna Pharmaceuticals lnc.
  • 31.13. SomaGenics Inc.
  • 31.14. Wave Life Sciences Ltd.
  • 31.15. Exicure Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking

33. Global Oligonucleotide Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market Future Outlook and Potential Analysis

  • 35.1 Oligonucleotide Therapy Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Oligonucleotide Therapy Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Oligonucleotide Therapy Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer